2017 Evestra, Inc.

Over Active Bladder (OAB)

The number of women suffering from OAB is estimated to be 17 million in the US and between 50 and 100 million worldwide. However, recent studies suggest that the prevalence of OAB may actually be higher since many cases remain unreported for shame reasons, and the number of cases will continue to increase with an aging population in many parts of the world. Although OAB can have a significant effect on quality of life, there are still high dropout rates during treatment due to side effects. Therefore, there is a significant unmet medical need for new drugs with better tolerance and fewer side effects.

Treatments vary by type of incontinence

 Therapy based on antimuscarinic agents is limited by adverse side effects.

 In the event that medication does not work, women may opt for surgical treatment.

 Surgical treatment for SUI is among the most common surgeries in women.

Evestra is working on developing a vaginal ring product for the treatment of urinary incontinence/overactive bladder. The advantages of vaginal delivery via ring are the avoidance of plasma peaks and enabling targeted therapy. The overall effect is improved safety while maintain efficacy.

Several subtypes of urinary incontinence:

stress urinary incontinence (SUI), involuntary leakage on effort or exertion, or upon sneezing or coughing

urge urinary incontinence, or wet overactive bladder, involuntary leakage accompanied by or immediately proceeded by urgency

mixed urinary incontinence a combination of both stress and urge urinary incontinence